“Global primary cell culture market revenue is expected to reach $1.80 billion by 2029 at a CAGR of 8.7%”, says Visiongain

08 January 2020
Pharma

Visiongain’s new report the Primary Cell Culture Market Report 2019-2029: Forecasts by Origin (Hematopoietic Cells, Skin Cells, Gastrointestinal Cells, Liver Cells, Lung Cells, Renal Cells, Muscle Cells, Other Cells), by Type (Human, Animal), by End User (Life Science Research Companies, Research Institutes), plus analysis of leading companies operating in the global primary cell culture market.

Fewer chances of mutations and modifications, reducing testing cost, growing production of regenerative medicines, rising research & development in biotechnology and increasing demand for stem cell therapy is expected to drive global primary cell culture market over the projected period. In 2019, global primary cell culture market revenue was valued at $779 million and is expected to reach $1.80 billion by 2029 at a CAGR of 8.7%. Other major factors driving the growth of primary cell culture market are growing prevalence of cancer and other chronic diseases all over the world. According to the National Cancer Institute, in 2018, more than 1.5 million new cases of cancer were diagnosed in the United States and more than 600k people died from cancer.

The drain of chronic diseases is rapidly increasing worldwide. According to the World Health Organization, in 2001, chronic diseases contributed approximately 60% of the 56.5 million total reported deaths in the world and approximately 46% of the global burden of disease. The proportion of the burden of chronic diseases is expected to increase to 57% by 2020. This, in turn, is expected to propel the primary cell culture industry over the coming years.

By region, North America dominated the global primary cell culture industry in 2019 and is expected to grow by virtue of technological advancement followed by well-developed healthcare infrastructure. Additionally, development and introduction of cell culture technologies coupled with increasing adoption of advanced therapies in Canada, the United States, and Mexico are expected to help market expansion over the coming years. Moreover, hectic lifestyle, increasing working hours, increasing working population, and consumer trends towards unhealthy foods has increased prevalence of chronic diseases in this region, which is expected to encourage primary cell culture industry over the projected period.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

Read

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

Read

Visiongain Publishes Clinical Perinatal Software Market Report 2020-2030

Various research studies are currently underway, which are expected to create a competitive advantage for manufacturers to develop new and innovative and advanced software that is expected to provide a variety of additional opportunities in the perinatal clinical software market.

01 July 2020

Read

Visiongain publishes Clinical Laboratory Tests Market Report 2020-2030

Growing investment in target diagnosis of cardiovascular disorders, TB and diabetes drives demand for clinical laboratory testing. Clinical lab tests help in diagnosing mellitus diabetes. According to the International Diabetes Federation article published in 2019, some 463 million adults were diabetic, and it is estimated that it will reach 700 million worldwide by 2045.

01 July 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever